The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Presurgical Chemotherapy Compared With Immediate Surgery and Adjuvant Chemotherapy for Nonmetastatic Osteosarcoma: Pediatric Oncology Group Study POG-8651
Abstract
Purpose: Successful therapeutic interventions to prevent disease progression in patients with nonmetastatic osteosarcoma have included surgery with adjuvant chemotherapy. Presurgical chemotherapy has been advocated for these patients because of putative improvement in event-free survival (EFS). The advantages of presurgical chemotherapy include early administration of systemic chemotherapy, shrinkage of primary tumor, and pathologic identification of risk groups. The theoretic disadvantage is that it exposes a large tumor burden to marginally effective chemotherapy. The contribution of chemotherapy and surgery timing has not been tested rigorously. Patients and Methods: Between 1986 and 1993, we conducted a prospective trial in patients with nonmetastatic osteosarcoma who were assigned randomly to immediate surgery or presurgical chemotherapy. Except for the timing of surgery (week 0 or 10), patients received 44 weeks of identical combination chemotherapy that included high-dose methotrexate with leucovorin rescue, doxorubicin, cisplatin, bleomycin, cyclophosphamide, and dactinomycin. Results: One hundred six patients were enrolled onto this study. Six were excluded from analysis. Of the remaining 100 patients, 45 were randomly assigned to immediate chemotherapy, and 55 were randomly assigned to immediate surgery. Sixty-seven patients remain disease-free. At 5 years, the projected EFS ± SE is 65% ± 6% (69% ± 8% for immediate surgery and 61% ± 8% for presurgical chemotherapy; P = .8). The treatment arms had similar incidence of limb salvage (55% for immediate surgery and 50% for presurgical chemotherapy). Conclusion: Chemotherapy was effective in both treatment groups. There was no advantage in EFS for patients given presurgical chemotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., & Smith, P. G. (1977) · British Journal of Cancer · doi:10.1038/bjc.1977.1 · Cited by 8,285
Asymptotically Efficient Rank Invariant Test Procedures
Peto, R., & Peto, J. (1972) · Journal of the Royal Statistical Society. Series A (General) · doi:10.2307/2344317 · Cited by 3,393
Bielack, S. S., Kempf-Bielack, B., Delling, G., Exner, G. U., Flege, S., Helmke, K., Kotz, R., Salzer-Kuntschik, M., Werner, M., Winkelmann, W., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.3.776 · Cited by 2,393
Grier, H. E., Krailo, M. D., Tarbell, N. J., Link, M. P., Fryer, C. J. H., Pritchard, D. J., Gebhardt, M. C., Dickman, P. S., Perlman, E. J., Meyers, P. A., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020890 · Cited by 1,328
Self-citationLink, M. P., Goorin, A. M., Miser, A. W., Green, A. A., Pratt, C. B., Belasco, J. B., Pritchard, J., Malpas, J. S., Baker, A. R., Kirkpatrick, J. A., et al. (1986) · New England Journal of Medicine · doi:10.1056/nejm198606193142502 · Cited by 1,204
Self-citationRosen, G., Caparros, B., Huvos, A. G., Kosloff, C., Nirenberg, A., Cacavio, A., Marcove, R. C., Lane, J. M., Mehta, B., & Urban, C. (1982) · Cancer · doi:10.1002/1097-0142(19820315)49:6<1221::aid-cncr2820490625>3.0.co;2-e · Cited by 1,090
Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience.
Meyers, P. A., Heller, G., Healey, J., Huvos, A., Lane, J., Marcove, R., Applewhite, A., Vlamis, V, & Rosen, G. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.1.5 · Cited by 678
Primary Chemotherapy To Avoid Mastectomy in Tumors With Diameters of Three Centimeters or More
Bonadonna, G., Veronesi, U., Brambilla, C., Ferrari, L., Luini, A., Greco, M., Bartoli, C., Yoldi, G. C. D., Zucali, R., Rilke, F., et al. (1990) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/82.19.1539 · Cited by 607
Primary osteogenic sarcoma. The rationale for preoperative chemotherapy and delayed surgery
Rosen, G., Marcove, R. C., Caparros, B., Nirenberg, A., Kosloff, C., & Huvos, A. G. (1979) · Cancer · doi:10.1002/1097-0142(197906)43:6<2163::aid-cncr2820430602>3.0.co;2-s · Cited by 592
Adjuvant chemotherapy for osteosarcoma: a randomized prospective trial.
Eilber, F., Giuliano, A., Eckardt, J., Patterson, K., Moseley, S., & Goodnight, J. (1987) · Journal of Clinical Oncology · doi:10.1200/jco.1987.5.1.21 · Cited by 529
Provisor, A. J., Ettinger, L. J., Nachman, J. B., Krailo, M. D., Makley, J. T., Yunis, E. J., Huvos, A. G., Betcher, D. L., Baum, E. S., Kisker, C. T., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.1.76 · Cited by 461
Winkler, K., Beron, G., Delling, G., Heise, U., Kabisch, H., Purfürst, C., Berger, J., Ritter, J., Jürgens, H., & Gerein, V (1988) · Journal of Clinical Oncology · doi:10.1200/jco.1988.6.2.329 · Cited by 459
Recht, A., Come, S. E., Henderson, I. C., Gelman, R. S., Silver, B., Hayes, D. F., Shulman, L. N., & Harris, J. R. (1996) · New England Journal of Medicine · doi:10.1056/nejm199605233342102 · Cited by 436
Prognostic factors in osteosarcoma: a critical review.
Davis, A. M., Bell, R. S., & Goodwin, P. J. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.2.423 · Cited by 424
Souhami, R. L., Craft, A. W., Van der Eijken, J. W., Nooij, M., Spooner, D., Bramwell, V. H., Wierzbicki, R., Malcolm, A. J., Kirkpatrick, A., Uscinska, B. M., et al. (1997) · The Lancet · doi:10.1016/s0140-6736(97)02307-6 · Cited by 383
Neoadjuvant chemotherapy for osteogenic sarcoma: results of a Cooperative German/Austrian study.
Winkler, K., Beron, G., Kotz, R., Salzer-Kuntschik, M., Beck, J., Beck, W., Brandeis, W., Ebell, W., Erttmann, R., & Göbel, U. (1984) · Journal of Clinical Oncology · doi:10.1200/jco.1984.2.6.617 · Cited by 345
Fuchs, N., Bielack, S. S., Epler, D., Bieling, P., Delling, G., Körholz, D., Graf, N., Heise, U., Jürgens, H., Kotz, R., et al. (1998) · Annals of Oncology · doi:10.1023/a:1008391103132 · Cited by 343
Bramwell, V. H., Burgers, M., Sneath, R., Souhami, R., van Oosterom, A. T., Voûte, P. A., Rouesse, J., Spooner, D., Craft, A. W., & Somers, R. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.10.1579 · Cited by 313
Bacci, G., Picci, P., Ferrari, S., Ruggieri, P., Casadei, R., Tienghi, A., Prever, A. B. D., Gherlinzoni, F., Mercuri, M., & Monti, C. (1993) · Cancer · doi:10.1002/1097-0142(19931201)72:11<3227::aid-cncr2820721116>3.0.co;2-c · Cited by 294
Bacci, G., Picci, P., Ruggieri, P., Mercuri, M., Avella, M., Capanna, R., Brach Del Prever, A., Mancini, A., Gherlinzoni, F., Padovani, G., et al. (1990) · Cancer · doi:10.1002/1097-0142(19900601)65:11<2539::aid-cncr2820651125>3.0.co;2-m · Cited by 235
Primary osteogenic sarcoma: Eight-year experience with adjuvant chemotherapy
Rosen, G., Marcove, R. C., Huvos, A. G., Caparros, B. I., Lane, J. M., Nirenberg, A., Cacavio, A., & Groshen, S. (1983) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/bf00625054 · Cited by 228
Goorin, A. M., Pérez‐Atayde, A. R., Gebhardt, M. C., Andersen, J. W., Wilkinson, R. H., Delorey, M. J., Watts, H. G., Link, M. P., Jaffe, N., & Frei, E. (1987) · Journal of Clinical Oncology · doi:10.1200/jco.1987.5.8.1178 · Cited by 125
Self-citationKrailo, M., Ertel, I. J., Makley, J. T., Fryer, C. J., Baum, E. S., Weetman, R. M., Yunis, E. J., Barnes, L. E., Bleyer, W. A., & Hammond, G. D. (1987) · Medical and Pediatric Oncology · doi:10.1002/mpo.2950150205 · Cited by 75
FRENCH BONE TUMOR STUDY GROUP, & The following members of the French Bone Tumor Study Group participated in this study: A. Trifaud (President), M. (1988) · Cancer · Cited by 47
Primary chemotherapy: concepts and issues.
Muggia, F. M. (1985) · PubMed · Cited by 4
Cited by
Osteosarcoma: Current Treatment and a Collaborative Pathway to Success
Isakoff, M. S., Bielack, S. S., Meltzer, P., & Gorlick, R. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.4895 · Cited by 1,567
Osteosarcoma treatment – Where do we stand? A state of the art review
Luetke, A., Meyers, P. A., Lewis, I., & Juergens, H. (2014) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2013.11.006 · Cited by 1,234
Ritter, J., & Bielack, S. S. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq276 · Cited by 1,045
Advancing therapy for osteosarcoma
Gill, J., & Gorlick, R. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00519-8 · Cited by 876
Preventing and Managing Toxicities of High-Dose Methotrexate
Howard, S. C., McCormick, J., Pui, C.-H., Buddington, R. K., & Harvey, R. D. (2016) · The Oncologist · doi:10.1634/theoncologist.2015-0164 · Cited by 929
Metadata
- Authors
- Goorin, A. M., Schwartzentruber, D. J., Devidas, M., Gebhardt, M. C., Ayala, A. G., Harris, M. B., Helman, L. J., Grier, H. E., & Link, M. P.
- Venue
- Journal of Clinical Oncology
- Published
- 2003-04-15
- Volume
- 21
- Issue
- 8
- Pages
- 1574-1580
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2165678358
- Cited by
- 395
- References
- 27
- FWCI
- 10.17
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.